CL
64
3
AAL
32
-4
MTCH
50
2
ETR
58
-2
CHK
43
2
NTAP
65
4
DO
58
6
PXD
48
-6
V
66
-2
WRK
59
3
CRM
49
5
GILD
28
2
RIG
50
4
INTC
36
-5
APH
73
2
THC
70
-2
AVGO
52
8
KR
64
8
GIS
61
-2
PRGO
66
9
CL
64
3
AAL
32
-4
MTCH
50
2
ETR
58
-2
CHK
43
2
NTAP
65
4
DO
58
6
PXD
48
-6
V
66
-2
WRK
59
3
CRM
49
5
GILD
28
2
RIG
50
4
INTC
36
-5
APH
73
2
THC
70
-2
AVGO
52
8
KR
64
8
GIS
61
-2
PRGO
66
9
Financhill
Back

Atara Biotherapeutics 10K Form

Sell
23

ATRA
Atara Biotherapeutics

Last Price:
0.69
Seasonality Move:
-9.8%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ATRA News And Ratings

See the #1 stock for the next 7 days that we like better than ATRA

ATRA Financial Statistics

Sales & Book Value

Annual Sales: $8.57M
Cash Flow: $-50.45M
Price / Cash Flow: 0
Annual Sales: $-0.93
Price / Book: 0

Profitability

EPS (TTM): -2.62000
Net Income (TTM): $-276.13M
Gross Margin: $-313K
Return on Equity: -2818.48%
Return on Assets: -107.93%

Atara Biotherapeutics Earnings Forecast

Key Atara Biotherapeutics Financial Ratios

  • The Gross Profit Margin over the past 6 years for ATRA is -3.65%.
  • The Selling, General & Administrative Expenses for ATRA have been equal to 593.82% of Gross Profit Margin.
  • The Research & Development expenses have been 2,622.01% of Revenue.
  • The Interest Expense is -1.91% of Operating Income.
  • The Net Earning history of ATRA is -3,220.88% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 4 years.

Atara Biotherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ATRA
CUSIP: 046513
Website: atarabio.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0.72
Quick Ratio: 0.6

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ATRA Technical Analysis vs Fundamental Analysis

Sell
23
Atara Biotherapeutics (ATRA) is a Sell

Is Atara Biotherapeutics a Buy or a Sell?